Today
Where to start today.
What to watch
No confirmed events in the near term. The events directory tracks every dated move.
More coverage
The rest of today’s briefing.
.webp&w=2520&q=75)
Coverage
Science and lifestyle
Coverage
Capital and public markets
Coverage
Industry and regulation
Markets
38 tracked- Nutromics
April 2026: Nutromics was awarded about A$3m within a A$11.2m Cooperative Research Centres Projects consortium to develop a sepsis management patch, and appointed Tom Prescott as Board Chair ahead of a planned 2027 commercial launch (company media page, nutromics.com/media). Earlier, in October 2025 it presented what it described as the first real-time in vivo multiplexed data measuring vancomycin and tobramycin simultaneously on one device at IATDMCT.
- Atisama Therapeutics (formerly RAGE Biotech / Rage Bio Pty Ltd)
15 May 2026: now operating as Atisama Therapeutics, the company announced RB042 had advanced into multiple ascending dose cohorts of its Phase 1 trial after completing three of four single ascending dose cohorts, with readouts expected in H2 2026, and appointed Bernard Coulie as Chair of the Board (source: Atisama press release carried by FNArena, 16 May 2026). This followed the A$29m Series A announced 13 November 2025, led by IP Group Australia and Hostplus with Monash Ventures.
Every claim traced to a named source and evidence-graded. See how at editorial standards, or the public corrections log.